Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Moodys
Medtronic
Colorcon

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Netazepide

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Netazepide?

Netazepide is an investigational drug.

There have been 6 clinical trials for Netazepide. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2011.

The most common disease conditions in clinical trials are Carcinoid Tumor, Atrophy, and Barrett Esophagus. The leading clinical trial sponsors are Trio Medicines Ltd., University of Cambridge, and National Institute for Health Research, United Kingdom.

There are five US patents protecting this investigational drug and seventy-three international patents.

Recent Clinical Trials for Netazepide
TitleSponsorPhase
YF476 in Barrett's EsophagusColumbia UniversityPhase 2
YF476 in Barrett's EsophagusUniversity of CambridgePhase 2
YF476 in Barrett's EsophagusTrio Medicines Ltd.Phase 2

See all Netazepide clinical trials

Clinical Trial Summary for Netazepide

Top disease conditions for Netazepide
Top clinical trial sponsors for Netazepide

See all Netazepide clinical trials

US Patents for Netazepide

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Netazepide   Start Trial Benzodiazepine derivatives as CCK2/gastrin receptor antagonists TRIO MEDICINES LTD (Brighton East Sussex, GB)   Start Trial
Netazepide   Start Trial Benzodiazepine derivatives useful as CCK-receptor antagonists Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, JP)   Start Trial
Netazepide   Start Trial Process of preparing benzodiazepine compounds useful as antagonists of CCK or of gastrine Ferring-Research Limited (Middlesex, GB) Yamanouchi Pharmaceutical Co. Ltd. (Tokyo, JP)   Start Trial
Netazepide   Start Trial Benzodiazepin derivatives useful as CCK-receptor antagonists Ferring BV (NL) Yamanouchi Pharmaceutical Co. Ltd. (Tokyo, JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Netazepide

Drugname Country Document Number Estimated Expiration Related US Patent
Netazepide Australia 2015298476 2034-08-08   Start Trial
Netazepide Brazil 112017002389 2034-08-08   Start Trial
Netazepide Canada 2954583 2034-08-08   Start Trial
Netazepide China 106715411 2034-08-08   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Merck
Johnson and Johnson
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.